Welcome to our dedicated page for Wave Life Scienc SEC filings (Ticker: WVE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Wave Life Sciences’ SEC disclosures can feel like decoding a lab notebook packed with stereochemistry graphs and clinical-trial acronyms. Cash runway, safety signals, and partnership milestones often hide in footnotes that stretch past page 200. If you are searching for “Wave Life Sciences SEC filings explained simply,” this page was built for you.
Stock Titan’s AI spots what matters in seconds. Whether you need the full “Wave Life Sciences quarterly earnings report 10-Q filing,” the latest 8-K data-readout alert, or “Wave Life Sciences insider trading Form 4 transactions,” our platform delivers real-time documents and plain-language summaries side-by-side. Click any form type—10-K, 10-Q, S-3, or “Wave Life Sciences proxy statement executive compensation”—and see highlighted sections on R&D spend, clinical endpoints, or dilution risk. Our algorithms turn technical tables into trend lines, making “understanding Wave Life Sciences SEC documents with AI” part of your regular workflow rather than a weekend project.
Need to track management sentiment? Receive instant notifications on “Wave Life Sciences Form 4 insider transactions real-time” and dig into grant prices or post-data stock sales under “Wave Life Sciences executive stock transactions Form 4.” Preparing for catalyst events? The AI-driven dashboard links every “Wave Life Sciences 8-K material events explained” to prior disclosures so you can see how guidance evolves. And when the annual report drops, the “Wave Life Sciences annual report 10-K simplified” section distills complex risk factors and pipeline updates into crisp bullet points you can cite immediately.
Wave Life Sciences director Aik Na Tan executed a Rule 10b5-1 plan transaction on 08/15/2025 that exercised and sold share options. The reporting person exercised 21,000 vested options at an exercise price of $9.13 per share, receiving 21,000 ordinary shares, and simultaneously sold 21,000 shares at $9.25 per share. Following these transactions the reporting person beneficially owned 40,388 ordinary shares, down from 61,388 before the sale. The 10b5-1 plan was adopted on March 13, 2025. The Form 4 is signed by Aik Na Tan on 08/19/2025.
Wave Life Sciences (WVE) Form 144 notices a proposed sale of 21,000 common shares by a person who exercised stock options on 08/15/2025 and intends to sell through Morgan Stanley Smith Barney LLC on NASDAQ at an aggregate market value of $194,250.00. The filing reports 159,140,460 shares outstanding. The same account sold 1,127 shares on 08/05/2025 for gross proceeds of $9,861.25. The seller represents they are not aware of undisclosed material adverse information about the issuer.
Form 4 filed for Wave Life Sciences (WVE) reports director compensation awards and large Fund holdings. On 08/11/2025 RA Capital entities and affiliated individuals disclosed awards and holdings related to Dr. Peter Kolchinsky, a director. The filing shows a grant of 12,700 restricted share units (RSUs) and an award of 76,200 share options with an $8.105 exercise price. The RSUs and options vest on the earlier of the issuer's 2026 annual general meeting or August 11, 2026, and the options expire August 11, 2030.
The filing further reports 28,815 shares beneficially owned following the reported transaction(s) (indirect) and that RA Capital Healthcare Fund, L.P. directly holds 18,202,009 shares. Footnotes state the RSUs/options are held for the benefit of the Fund and that the reporting parties disclaim beneficial ownership except for pecuniary interest.
Mark Corrigan, a director of Wave Life Sciences Ltd. (WVE), received equity awards on 08/11/2025 under the company’s 2025 Non-Employee Director Compensation Policy. The filing shows a grant of 12,700 restricted share units (RSUs) and a grant of a share option for 76,200 ordinary shares with an exercise price of $8.105. These awards were reported on a Form 4 disclosing insider activity.
The RSUs vest 100% on the earlier of the company’s 2026 annual general meeting or August 11, 2026. The option also vests 100% by that same earlier date and has an expiration date of 08/11/2030. After the reported transactions, the filing shows the reporting person beneficially owns 44,930 ordinary shares and holds 76,200 options referenced in the filing.
Wave Life Sciences Ltd. (WVE) Director Aik Na Tan reported equity awards on 08/11/2025 under the company’s 2025 Non-Employee Director Compensation Policy. The filing shows a grant of 25,400 restricted share units (RSUs) that vest 50% on the earlier of the 2026 annual general meeting or August 11, 2026 and 50% on the earlier of the 2027 annual general meeting or August 11, 2027. The reporting person was also granted a share option for 152,400 ordinary shares with an exercise price of $8.105, vesting 12.5% quarterly beginning August 11, 2025 over two years and expiring on 08/11/2030. After these reported transactions the form lists 40,388 ordinary shares and 152,400 derivative securities beneficially owned by the reporting person.
Ken Takanashi, a director of Wave Life Sciences Ltd. (WVE), received equity awards under the company’s 2025 Non-Employee Director Compensation Policy. On 08/11/2025 he was granted 12,700 restricted share units (RSUs) that vest 100% on the earlier of the 2026 annual general meeting or August 11, 2026, and options to purchase 76,200 ordinary shares with an exercise price of $8.105 that vest on the same schedule and list an expiration date of 08/11/2030. The form reports these grants as compensation at a $0.00 price and shows 5,729,003 ordinary shares and 76,200 derivative securities beneficially owned following the transactions.
Heidi L. Wagner, a director of Wave Life Sciences Ltd. (WVE), received equity awards on 08/11/2025 under the 2025 Non-Employee Director Compensation Policy. The filing shows a grant of 12,700 restricted share units (RSUs) that vest 100% on the earlier of the company’s 2026 annual general meeting or August 11, 2026. Following the reported transactions, the reporting person beneficially owns 44,930 ordinary shares directly.
The filing also discloses a share option covering 76,200 ordinary shares with an exercise price of $8.105, shown as acquired on 08/11/2025 and expiring on 08/11/2030. That option vests 100% on the earlier of the 2026 annual general meeting or August 11, 2026, and is reported as 76,200 derivative securities beneficially owned following the transaction.
HENRY CHRISTIAN O, a director of Wave Life Sciences Ltd. (WVE), reported compensation and trading activity. The director was granted 12,700 restricted share units (RSUs) and 76,200 share options under the 2025 Non-Employee Director Compensation Policy, with both awards vesting 100% on the earlier of the companys 2026 annual general meeting or August 11, 2026. The reporting person also sold 9,670 ordinary shares pursuant to a Rule 10b5-1 trading plan adopted November 24, 2024, at a weighted-average price of $8.81 per share (sales ranged $8.45 to $9.03). Following these transactions the report lists 29,645 ordinary shares and 76,200 options beneficially owned, held directly.
Wave Life Sciences director Adrian Rawcliffe received equity awards on 08/11/2025 comprising both restricted share units and stock options. The filing shows a grant of 12,700 restricted share units (RSUs) and a grant of 76,200 options with an exercise price listed as $8.105. The RSUs and options vest as to 100% on the earlier of the company’s 2026 annual general meeting or August 11, 2026, and the option listing shows an expiration date of 08/11/2030. The filing reports 28,815 ordinary shares beneficially owned by Rawcliffe following these awards. These items are recorded as director compensation under the company’s 2025 Non-Employee Director Compensation Policy.
Gregory L. Verdine, a director of Wave Life Sciences Ltd. (WVE), received director compensation consisting of 12,700 restricted share units (RSUs) and a share option covering 76,200 ordinary shares with an exercise price of $8.105. Following the RSU grant, his reported direct beneficial ownership is 295,217 ordinary shares.
The RSUs vest 100% on the earlier of the company’s 2026 annual general meeting or August 11, 2026. The option vests on the same schedule and has an expiration date of August 11, 2030. Both awards were granted under the 2025 Non-Employee Director Compensation Policy.
FAQ
What is the current stock price of Wave Life Scienc (WVE)?
What is the market cap of Wave Life Scienc (WVE)?
